RLYB Rallybio Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%
Returns
ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $858,000 | $636,000 | — | — | — |
| R&D expense | $19.60M | $41.51M | $53.54M | $40.69M | $26.91M |
| SG&A expense | $14.32M | $19.62M | $25.39M | $27.20M | $18.74M |
| Operating income | -$33.06M | -$60.50M | -$78.93M | -$67.88M | -$45.65M |
| Interest expense | — | — | — | $0 | $10,000 |
| Pretax income | -$8.98M | -$55.54M | -$72.52M | -$65.58M | -$45.51M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M |
| EBITDA | -$32.97M | -$60.37M | -$78.78M | -$67.72M | -$45.54M |
| EPS (basic) | -1.59 | -10.61 | -1.84 | -2.09 | -1.84 |
| EPS (diluted) | -1.59 | -10.61 | -1.84 | -2.09 | -1.84 |
| Weighted avg. shares (diluted) | 5.63M | 5.44M | 40.45M | 31.82M | 25.52M |
| Balance sheet | |||||
| Cash & equivalents | $31.37M | $13.90M | $24.49M | $56.96M | $175.33M |
| Short-term investments | $23.36M | $51.61M | $85.44M | $112.04M | $0 |
| Current assets | $61.25M | $67.84M | $114.79M | $179.50M | $180.87M |
| PP&E, net | $23,000 | $115,000 | $246,000 | $385,000 | $511,000 |
| Total assets | $62.26M | $68.11M | $115.62M | $180.44M | $182.19M |
| Current liabilities | $4.22M | $6.24M | $9.26M | $10.74M | $6.55M |
| Total liabilities | $4.30M | $6.45M | $9.44M | $11.12M | $6.58M |
| Shareholders' equity | $57.96M | $61.65M | $106.18M | $169.32M | $175.60M |
| Shares outstanding | 5.28M | 5.19M | 37.83M | 37.84M | 32.13M |
| Cash flow statement | |||||
| Operating cash flow | -$29.81M | -$49.28M | -$60.27M | -$57.28M | -$45.53M |
| Capital expenditure | — | $0 | $12,000 | $54,000 | $333,000 |
| Free cash flow | — | -$49.28M | -$60.28M | -$57.34M | -$45.87M |
| Investing cash flow | $47.27M | $33.49M | $27.66M | -$112.17M | -$2.33M |
| Financing cash flow | $16,000 | $5.20M | $143,000 | $51.08M | $82.97M |
| Depreciation & amortization | $92,000 | $131,000 | $150,000 | $167,000 | $109,000 |
| Stock-based compensation | $5.31M | $7.99M | $10.92M | $9.50M | $3.65M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.